leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix announces appointment of David Cocke as its chief financial officer with immediate effect

Cocke has over 29 years of experience in the medical device industry holding senior finance and operations positions and In 1997, he founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical device

Handshake
NuPak Medical was acquired by Katena Products, Inc. in 2017 and Cocke remained with the business post-acquisition until early 2021

Tissue Regenix PLC (LON:TRX), the regenerative medical devices company, announced that it has appointed David Cocke as its chief financial officer (CFO) and director to the board with immediate effect.

The company noted that Cocke has over 29 years of experience in the medical device industry holding senior finance and operations positions. In 1997, he founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical devices, with the company turning cash flow positive in two years and growing the production volume from 50,000 to 3mln over time.

NuPak Medical was acquired by Katena Products, Inc. in 2017 and Cocke remained with the business post-acquisition until early 2021, leading the expansion to double the cleanroom capacity and assembly space on-time and on-budget.

READ: Tissue Regenix says it intends to appoint Brian Phillips and Trevor Phillips (no relation) as independent non-executive directors

It said Cocke was also chief financial officer at Aperion Biologics from 2008-2017 and supported the board in raising $21mln from venture capital and private investors. Prior to this, he was senior director for Finance and Operations at Kinetic Concepts from 1993-1996.

In a statement, Daniel Lee, the chief executive officer of Tissue Regenix commented: "David is a well-respected finance professional in the medical device industry. His experience of implementing financial systems and management as well as operations, will be invaluable to the Group as we undertake the next stages of our capacity expansion programme. Having worked with David previously at Aperion Biologics I have seen first-hand the value he brings to a business and I am happy to welcome him to the Tissue Regenix Group."

Quick facts: Tissue Regenix Group PLC

Price: 0.715 GBX

AIM:TRX
Market: AIM
Market Cap: £50.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix Group says 'maintaining level of sales is true testament to...

Tissue Regenix Group PLC's (LON:TRX) Daniel Lee talks to Proactive London about his experience in the sector, his new appointment as CEO as well the firm's performance for 2020.  In a trading update for the year to December 31, Lee says the revenues for the year will be £12.8mln, in line...

3 weeks, 2 days ago

2 min read